Use of bluetongue virus proteins as vaccine components
US5833995A · kind A · utility
1Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 18, 1994 |
| Grant date | Nov 10, 1998 |
| Priority date | — |
| Expiry date | Aug 18, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/924
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A protective effect against bluetongue infection in susceptible mammals which is obtained by innoculating said mammals with a polypeptide comprising at least an antigenic portion of bluetongue virus structural protein VP2 in antigenic form produced by transforming a host with a recombinant expression vector having a DNA segment coding for said polypeptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.